Oculis Holding AG

DB:CR5 Stock Report

Market Cap: €691.7m

Oculis Holding Valuation

Is CR5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CR5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: Insufficient data to calculate CR5's future cash flow value for valuation analysis.

Significantly Below Future Cash Flow Value: Insufficient data to calculate CR5's future cash flow value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CR5?

Key metric: As CR5 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for CR5. This is calculated by dividing CR5's market cap by their current book value.
What is CR5's PB Ratio?
PB Ratio2.9x
BookCHF 219.34m
Market CapCHF 646.99m

Price to Book Ratio vs Peers

How does CR5's PB Ratio compare to its peers?

The above table shows the PB ratio for CR5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.4x
DMP Dermapharm Holding
2.7x6.98%€2.0b
28L PEPTONIC medical
0.9xn/a€1.2b
93M1 MPH Health Care
0.4x57.89%€99.8m
HIGH Cantourage Group
1.5x51.71%€72.6m
CR5 Oculis Holding
2.9x13.59%€807.8m

Price-To-Book vs Peers: CR5 is expensive based on its Price-To-Book Ratio (2.9x) compared to the peer average (1.4x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does CR5's PB Ratio compare vs other companies in the DE Pharmaceuticals Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
NV5 AcuCort
0.04xn/aUS$239.71m
L7R Lipidor
0.1xn/aUS$92.68k
7IZ Ziccum
0.1xn/aUS$30.58k
No more companies available in this PB range
CR5 2.9xIndustry Avg. 2.8xNo. of Companies3PB01.63.24.86.48+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: CR5 is expensive based on its Price-To-Book Ratio (2.9x) compared to the European Pharmaceuticals industry average (2.8x).

Price to Book Ratio vs Fair Ratio

What is CR5's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CR5 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.9x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate CR5's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CR5 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€11.00
€31.11
+182.86%
20.36%€38.72€17.31n/a10
Aug ’27€9.56
€31.40
+228.41%
18.57%€37.97€19.50n/a10
Jul ’27€11.55
€32.90
+184.88%
20.59%€44.90€19.69n/a11
Jun ’27€12.60
€34.65
+175.03%
15.78%€45.33€22.37n/a11
May ’27€21.50
€40.51
+88.43%
12.92%€47.96€31.99n/a10
Apr ’27€21.80
€40.66
+86.50%
12.72%€48.16€32.13n/a10
Mar ’27€24.40
€38.53
+57.91%
18.76%€48.25€25.17n/a10
Feb ’27€22.90
€38.53
+68.26%
18.76%€48.25€25.17n/a10
Jan ’27n/a
€38.21
0%
18.96%€47.60€24.83n/a10
Dec ’26€16.00
€37.60
+135.00%
20.25%€48.03€25.05n/a8
Nov ’26€18.00
€36.67
+103.71%
21.08%€47.54€25.59n/a8
Oct ’26€14.35
€31.57
+119.98%
17.72%€43.01€24.00n/a7
Sep ’26€13.10
€31.99
+144.19%
16.69%€43.06€24.02n/a8
Aug ’26€14.65
€32.70
+123.18%
16.91%€42.76€24.86€9.567
Jul ’26n/a
€32.76
0%
17.78%€43.80€24.78€11.557
Jun ’26n/a
€29.15
0%
18.83%€36.83€19.16€12.607
May ’26n/a
€29.12
0%
18.38%€35.93€19.28€21.507
Apr ’26n/a
€29.44
0%
18.12%€37.76€20.30€21.807
Mar ’26n/a
€29.94
0%
15.00%€34.56€21.22€24.407
Feb ’26n/a
€28.91
0%
14.21%€34.32€21.14€22.907
Jan ’26n/a
€26.95
0%
19.77%€34.51€18.88n/a7
Dec ’25n/a
€26.95
0%
19.77%€34.51€18.88€16.007
Nov ’25n/a
€26.32
0%
21.19%€33.39€18.20€18.006
Oct ’25€10.80
€26.09
+141.59%
21.19%€33.26€18.13€14.356
Sep ’25€10.60
€26.52
+150.17%
19.17%€33.33€19.17€13.106
Aug ’25€10.50
€26.73
+154.61%
21.40%€34.08€18.42€14.656
€30.28
Fair Value
63.7% undervalued intrinsic discount
10
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/23 15:35
End of Day Share Price 2026/08/21 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Oculis Holding AG is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
null nullBaird
Jason Matthew GerberryBofA Global Research